PD-1/PD-L1信号通路抑制剂在宫颈癌治疗中的研究进展

doi:10.3969/j.issn.1004-616x.2019.05.015

癌变·畸变·突变 ›› 2019, Vol. 31 ›› Issue (5): 417-420.doi: 10.3969/j.issn.1004-616x.2019.05.015

• 综述 • 上一篇

PD-1/PD-L1信号通路抑制剂在宫颈癌治疗中的研究进展

徐苗, 张天一, 田菲菲

西南交通大学生命科学与工程学院, 四川成都 610031

收稿日期:2018-10-10 修回日期:2019-08-27 出版日期:2019-09-30 发布日期:2019-10-09
通讯作者: 田菲菲,E-mail:tulwar@home.swjtu.edu.cn E-mail:tulwar@home.swjtu.edu.cn
作者简介:徐苗,E-mail:xu.miao1022@qq.com。
基金资助:
国家自然科学基金（31601066）

Received:2018-10-10 Revised:2019-08-27 Online:2019-09-30 Published:2019-10-09

摘要/Abstract

摘要： 程序性死亡配体1（PD-L1）是一种免疫抑制性共刺激分子，其与程序性死亡受体1（PD-1）结合可以抑制T细胞增殖分化并导致T细胞凋亡。多种肿瘤细胞通过大量表达PD-L1使肿瘤细胞逃避免疫系统的监视与攻击。PD-1/PD-L1信号通路抑制剂作为免疫疗法中的一个重要方法正在被进行广泛的研究，与现有疗法相比，以PD-1/PD-L1信号通路抑制剂为代表的免疫疗法在癌症治疗中表现出良好的疗效和较少不良反应，但也存在不检查生物标志物直接进行无差别治疗时响应率不高等问题。本文就PD-1/PD-L1信号通路抑制剂与宫颈癌治疗的研究进展加以综述。

关键词: PD-1/PD-L1信号通路, 宫颈癌, 免疫逃逸, 免疫治疗

中图分类号:

R737.33

徐苗, 张天一, 田菲菲. PD-1/PD-L1信号通路抑制剂在宫颈癌治疗中的研究进展[J]. 癌变·畸变·突变, 2019, 31(5): 417-420.

参考文献

[1] WARDAK S. Human papillomavirus (HPV) and cervical cancer[J]. Med Dosw Mikrobiol, 2016, 68(1):73-84.
[2] GUO F J, COFIE L E, BERENSON A B. Cervical cancer incidence in young US females after human papillomavirus vaccine introduction[J]. Am J Prev Med, 2018, 55(2):197-204.
[3] HE Y Y, YU H, ROZEBOOM L, et al. LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes[J]. J Thorac Oncol, 2017, 12(5):814-823.
[4] KIM J M, CHEN D S. Immune escape to PD-L1/PD-1 blockade:seven steps to success (or failure)[J]. Ann Oncol, 2016, 27(8):1492-1504.
[5] ISHIDA Y, AGATA Y, SHIBAHARA K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895.
[6] SUN H Y, SUN C, XIAO W H. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations[J]. Cytokine, 2014, 65(1):33-41.
[7] MAMALIS A, GARCHA M, JAGDEO J. Targeting the PD-1 pathway:a promising future for the treatment of melanoma[J]. Arch Dermatol Res, 2014, 306(6):511-519.
[8] ZAK K M, KITEL R, PRZETOCKA S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1[J]. Structure, 2015, 23(12):2341-2348.
[9] SHEN X, ZHAO B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer:meta-analysis[J]. BMJ, 2018, 362:k3529.
[10] MARZEC M, ZHANG Q, GORADIA A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274(PD-L1, B7-H1)[J]. Proc Natl Acad Sci U S A, 2008, 105(52):20852-20857.
[11] QIN B D, JIAO X D, ZANG Y S. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy[J]. Med Hypotheses, 2018, 116:111-113.
[12] CHEN J, JIANG C C, JIN L, et al. Regulation of PD-L1:a novel role of pro-survival signalling in cancer[J]. Ann Oncol, 2016, 27(3):409-416.
[13] BOUSSIOTIS V A. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016, 375(18):1767-1778.
[14] SUNSHINE J, TAUBE J M. PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015, 23:32-38.
[15] KATO S, GOODMAN A, WALAVALKAR V, et al. Hyperprogressors after immunotherapy:analysis of genomic alterations associated with accelerated growth rate[J]. Clin Cancer Res, 2017, 23(15):4242-4250.
[16] CHANG H N, LIU B Y, QI Y K, et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy[J]. Angew Chem Int Ed Engl, 2015, 54(40):11760-11764.
[17] LI C L, ZHANG N P, ZHOU J D, et al. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy[J]. Cancer Immunol Res, 2018, 6(2):178-188.
[18] 刘大纯, 王晓霜. 腹腔镜手术治疗宫颈癌的临床效果及对生存质量的影响[J]. 基因组学与应用生物学, 2018, 37(2):596-603.
[19] 邓丽霞, 刘鑫鑫, 陈斌, 等. 三维腔内放疗在宫颈癌ⅠB1期、ⅡA1期病灶直径3~4 cm患者术前治疗中的应用效果[J]. 中国医药导报, 2018, 15(3):102-106.
[20] SAGLAM O, CONEJO-GARCIA J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer[J]. Integr Cancer Sci Therap, 2018, 5(2):1-4.
[21] HEEREN A M, PUNT S, BLEEKER M C, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix[J]. Mod Pathol, 2016, 29(7):753-763.
[22] MENG Y, LIANG H Y, HU J G, et al. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer[J]. J Cancer, 2018, 9(16):2938-2945.
[23] YANG W, SONG Y, LU Y L, et al. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia[J]. Immunology, 2013, 139(4):513-522.
[24] LIU Z D, ZHOU H, WANG W J, et al. A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice[J]. Oncoimmunology, 2016, 5(6):e1147641. DOI:10.1080/2162402X.2016.1147641.
[25] MOEINI S, SAEIDI M, FOTOUHI F, et al. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine[J]. Arch Virol, 2017, 162(2):333-346.
[26] 魏洁, 寇蓬, 廉阳秧, 等. 阻断PD-L1/PD-1途径增强顺铂化疗效果的实验研究[J]. 实用医学杂志, 2016, 32(1):47-50.
[27] FRENEL J S, LE TOURNEAU C, O'NEIL B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer:results from the phase ib KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36):4035-4041.
[28] BOUSSIOS S, SERAJ E, ZARKAVELIS G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens:Where do we stand? A literature review[J]. Crit Rev Oncol Hematol, 2016, 108:164-174.
[29] GIBNEY G T, WEINER L M, ATKINS M B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy[J]. Lancet Oncol, 2016, 17(12):e542-e551.
[30] 赵碧霞, 谢文柳, 蒋佩佩, 等. 发展中国家接种人乳头瘤病毒疫苗的影响因素[J]. 现代生物医学进展, 2015, 15(20):3971-3974.

PD-1/PD-L1信号通路抑制剂在宫颈癌治疗中的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王晓舟, 李洪石, 于溪, 魏宁, 王梓瑛, 赫丽杰. 青藤碱对HPV阳性宫颈癌SiHa细胞增殖和侵袭的影响[J]. 癌变·畸变·突变, 2021, 33(6): 442-445.
[2]	方磊, 杨涛, 盛磊, 木塔力甫·艾买提, 齐鑫鑫, 艾尼娃尔·艾克木, 伊力亚尔·尼加提. 黑种草子总皂苷对人宫颈癌SiHa细胞生物学行为的影响[J]. 癌变·畸变·突变, 2021, 33(2): 143-148,152.
[3]	兰莉, 陈海丽, 徐蕾. RBMS3-AS3对宫颈癌细胞增殖、凋亡和侵袭的影响及作用机制[J]. 癌变·畸变·突变, 2020, 32(6): 438-443.
[4]	王媛媛, 陈依超, 郑洁, 彭燕燕, 王少洪. 汕头市妇女HPV-52感染与宫颈鳞状上皮病变的关系[J]. 癌变·畸变·突变, 2020, 32(4): 304-308.
[5]	盛磊, 武贵臻, 热娜古丽·热依木, 艾尼娃尔·艾克木. 新疆黑种草子总黄酮体外抗宫颈癌活性研究[J]. 癌变·畸变·突变, 2019, 31(5): 385-391.
[6]	郝轶, 袁建林, 肖悦, 李卉, 郭霞. 3种不同的HPV型别宫颈癌细胞株分泌蛋白非标记定量技术分析[J]. 癌变·畸变·突变, 2018, 30(5): 354-358,364.
[7]	迪拉热·力迪甫, 木塔力甫·艾买提, 盛磊, 古扎力努尔买提沙, 艾尔肯·肉孜比拉力, ABULIZI Abudula. HPV16编码蛋白与宫颈癌细胞内CALCA和TFPI-2表达的关系[J]. 癌变·畸变·突变, 2017, 29(6): 431-436.
[8]	宋淑芳, 常海平, 杨彩容, 赵荣伟, 张龙, 任杰, 郑健. 慢病毒介导的TPX2基因沉默对人宫颈癌HeLa细胞系增殖、迁移和细胞周期的影响及机制[J]. 癌变·畸变·突变, 2017, 29(5): 329-334,339.
[9]	刘好, 赵滢滢, 金平, 许改霞, 郭宇然, 张可, 王晓梅, 张蕾. 组蛋白去乙酰化酶抑制剂联合紫杉醇抑制宫颈癌细胞增殖的体外实验[J]. 癌变·畸变·突变, 2017, 29(5): 335-339.
[10]	丁立新, 赵现哲, 姜晓燕, 丁库克. 宫颈癌辐射敏感性相关基因的研究进展[J]. 癌变·畸变·突变, 2017, 29(5): 394-396,401.
[11]	沈伶, 许丽璇, 李小平, 胡桂英, 麦碧, 纪璇, 粟丽. 粤东地区妇女人乳头瘤病毒感染情况和亚型分布及其与宫颈癌的关系[J]. 癌变·畸变·突变, 2017, 29(3): 226-229.
[12]	刘平. 长链非编码RNA XIST和miR-101-3p在子宫颈癌组织中的表达及关系[J]. 癌变·畸变·突变, 2017, 29(2): 121-124.
[13]	盛磊, 茹明芳, 武贵臻, 杨云, 阿布力孜·阿布杜拉. 维吾尔族妇女宫颈癌患者的免疫状态及其与临床病理因素的关系[J]. 癌变·畸变·突变, 2016, 28(5): 369-371,376.
[14]	张雪杉, 缪芳, 曹晏宁, 张晓姝. 婆罗双树样基因2干扰对宫颈癌HeLa细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2016, 28(5): 359-363,368.
[15]	栗丽, 胡桂英, 吴宇丹, 沈伶. 薄层液基细胞学联合HPV-DNA检测在粤东地区宫颈癌筛查中的临床价值[J]. 癌变·畸变·突变, 2016, 28(4): 281-283,291.